5J90 Stock Chart & Stats
€1.29
--
Market closed
€1.29
--
Day’s Range― - ―
52-Week Range€0.72 - €5.22
Previous CloseN/A
VolumeN/A
Average Volume (3M)94.00
Market Cap
€3.90M
Enterprise Value€13.95
Total Cash (Recent Filing)€1.30M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta11.68
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding1,373,703
10 Day Avg. Volume182
30 Day Avg. Volume94
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio-59.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€6.35M
Bulls Say, Bears Say
Bulls Say
Revenue Growth TractionA near-term doubling of TTM revenue with positive gross profit signals improving commercial traction and product-market fit. Sustained top-line growth can absorb fixed R&D and production costs, shorten the path to operating leverage, and materially improve long-term viability if maintained.
Conservative Balance Sheet (No Debt)Zero net debt and positive equity reduce refinancing and interest-rate risk and give management optionality. This lower financial leverage provides structural resilience during funding cycles and supports strategic investments or partnerships without immediate debt servicing pressure.
Niche Platform With Structural DemandA platform addressing single-cell biology and advanced therapy workflows sits in a long-term growth segment (drug discovery, cell therapy, regenerative medicine). Durable, specialized lab tools can command repeatable sales to academia and industry, supporting steady addressable-market expansion.
Bears Say
Persistent UnprofitabilityOngoing negative operating and net results mean the business is not yet self-sustaining; prolonged losses can erode equity and force strategic compromises. Achieving durable profitability requires sustained revenue growth and margin expansion versus current deeply negative margins.
Negative Cash Flow / Cash BurnConsistent negative operating and free cash flow creates structural reliance on external financing. Cash burn limits autonomous reinvestment, heightens dilution risk from raises, and constrains the firm's ability to scale operations or fund late-stage commercialization without clear cash-flow improvement.
Dependence On External FundingMeaningful swings in equity indicate recurrent fundraising to sustain operations. Dependence on capital raises increases execution risk, potential dilution, and strategic vulnerability if market conditions tighten, making long-term planning and consistent investment more challenging.
5J90 FAQ
What was Fluicell AB’s price range in the past 12 months?
Fluicell AB lowest stock price was €0.72 and its highest was €5.22 in the past 12 months.
What is Fluicell AB’s market cap?
Fluicell AB’s market cap is €3.90M.
When is Fluicell AB’s upcoming earnings report date?
Fluicell AB’s upcoming earnings report date is Aug 21, 2026 which is in 18 days.
How were Fluicell AB’s earnings last quarter?
Fluicell AB released its earnings results on May 08, 2026. The company reported €0.22 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Fluicell AB overvalued?
According to Wall Street analysts Fluicell AB’s price is currently Overvalued.
Does Fluicell AB pay dividends?
Fluicell AB does not currently pay dividends.
What is Fluicell AB’s EPS estimate?
Fluicell AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fluicell AB have?
Fluicell AB has 1,373,703 shares outstanding.
What happened to Fluicell AB’s price movement after its last earnings report?
Fluicell AB reported an EPS of €0.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 52.862%.
Which hedge fund is a major shareholder of Fluicell AB?
Currently, no hedge funds are holding shares in DE:5J90
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fluicell AB
Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.